ArticleIn silico pharmacology2025
In-silico identification of COX-2 inhibitory phytochemicals from traditional medicinal plants: molecular docking, dynamics, and safety predictions.
Article in In silico pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Anti-Inflammatory Potential of 1-Aryl-6,7-Dimethoxy-1,2,3,4-Tetrahydroisoquinolines: Structure-Activity Relationship and COX-2 Binding.Molecules (Basel, Switzerland) · 2026Article
- Rational Design of Novel Inhibitors: Integrating 3D-QSAR and Molecular Dynamics.BioMed research international · 2026Article
- Pyrrolopyrimidine derivatives as dual COX-2/ACE2 inhibitors: design, synthesis, and anti-inflammatory evaluation.Frontiers in molecular biosciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation is an essential biological response that facilitates tissue repair and immune defense; however, chronic inflammation is associated with numerous pathological conditions, including cardiovascular diseases, autoimmune disorders, and cancer. Cyclooxygenase-2 (COX-2) is a key enzyme in this process, catalyzing the synthesis of pro-inflammatory prostaglandins, thus representing a critical target for anti-inflammatory therapies. Conventional COX-2 inhibitors, particularly non-steroidal anti-inflammatory drugs (NSAIDs), often have significant side effects, creating an urgent need for safer alternatives. This in-silico study evaluates the binding affinities of bioactive compounds from Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-025-00407-4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.